Abstract
TESTOSTERONE is widely used in the treatment of osteoporosis (1, 2) and of metastatic breast carcinoma (3). Improvement in well-being, appetite and general strength, decrease of bone pain, weight gain, recalcification of osteolytic lesions and shrinkage of soft-tissue metastases have been noted. However, hirsutism, acne, change of voice and of libido are disturbing side-reactions. In addition, the hypercalcemic syndrome has been observed in 10–15 per cent of patients with metastatic breast carcinoma who were treated with testosterone; this toxic side-reaction was thought to be due to stimulation of growth of the hormonally dependent tumor (4, 5). In view of these undesirable effects, several testosterone compounds have been assayed in the hope of finding a potent anabolic agent less androgenic than testosterone (6–8). The testosterone derivative 17-ethyl-19-nortestosterone (Nilevar1) was shown to have the greatest separation of androgenic and anabolic effects in rats (9, 10). The favorable ratio of anabol...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of clinical endocrinology and metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
